Australia’s Sirtex clears U.S. regulatory hurdle for Chinese buyout

(Reuters) – Liver cancer treatment maker Sirtex Medical (SRX.AX) said on Monday that the U.S. Federal Trade Commission cleared its $1.4 billion buyout by a Chinese consortium, clearing a major hurdle for the deal to go through.

The company had agreed last month to be taken over by Beijing-based CDH Investments and its partner, China Grand Pharmaceutical and Healthcare Holdings (0512.HK), which trumped a bid from U.S.-based Varian Medical Systems (VAR.N).

Sirtex, which has a large portion of its operations in the United States, received clearance for the buyout from Australia’s Foreign Investment Review Board earlier in the month.

Reporting by Ambar Warrick in Bengaluru; Editing by Stephen Coates



Learn More about trade signals

What do you think?

0 points
Upvote Downvote

Total votes: 0

Upvotes: 0

Upvotes percentage: 0.000000%

Downvotes: 0

Downvotes percentage: 0.000000%

Sports betting no easy fix for U.S. gaming’s most beleaguered industries

Asian shares fall on soft China data, trade war fears